Drug Trial Radar · NCT04576988
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
324
Actual
Start
Jan 25, 2021
Primary completion
Aug 26, 2022
Study completion Dec 6, 2022
Sponsor
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. The primary hypothesis of the study is that the participants receiving sotatercept will have improved 6-minute walk distance (6MWD) at 24 weeks compared to participants receiving placebo.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SotaterceptBiological
Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
PlaceboDrug
Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
Background PAH TherapyDrug
Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24Time frame: Baseline and Week 24
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 24 weeks
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 24 weeks
Locations
120 sites in 21 countries. Site status is shown where the registry gives one.
Arizona Pulmonary Specialists (Site 1010)
Phoenix, Arizona
Pulmonary Associates, PA (Site 1008)
Phoenix, Arizona
University of Arizona (Site 1006)
Tucson, Arizona
University of California San Diego Medical Center (Site 1002)
San Diego, California
University of California - Davis Medical Center (Site 1064)
Sherman Oaks, California
Stanford University Medical Center (Site 1024)
Stanford, California
Harbor UCLA Medical Center (Site 1028)
Torrance, California
University of Colorado Hospital (Site 1013)
Aurora, Colorado
The George Washington University Medical Faculty Associates (Site 1025)
Washington D.C., District of Columbia
Mayo Clinic Jacksonville (Site 1045)
Jacksonville, Florida
University of South Florida (Site 1043)
Tampa, Florida
The Emory Clinic (Site 1030)
Atlanta, Georgia
Norton Pulmonary Specialists (Site 1066)
Louisville, Kentucky
Tufts Medical Center - PPDS (Site 1012)
Boston, Massachusetts
Brigham and Women's Hospital (Site 1014)
Boston, Massachusetts
University of Michigan (Site 1011)
Ann Arbor, Michigan
University of Minnesota (Site 1062)
Minneapolis, Minnesota
Mayo Clinic (Site 1023)
Rochester, Minnesota
University of Kansas Medical Center (Site 1020)
Kansas City, Missouri
Washington University School of Medicine (Site 1022)
St Louis, Missouri
Nebraska Medical Center (Site 1053)
Omaha, Nebraska
Renown Institute for Heart & Vascular Health (Site 1055)
Reno, Nevada
New York Presbyterian Hospital (Site 1046)
New York, New York
Duke University Medical Center (Site 1026)
Durham, North Carolina
University of Cincinnati Medical Center (Site 1035)
Cincinnati, Ohio
The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital (Site 1001)
Cincinnati, Ohio
University Hospitals Cleveland Medical Center (Site 1005)
Cleveland, Ohio
The Ohio State University Wexner Medical Center (Site 1032)
Columbus, Ohio
Oregon Health and Science University (Site 1054)
Portland, Oregon
University of Pennsylvania (Site 1047)
Philadelphia, Pennsylvania
UPMC Presbyterian. UPMC Presbyterian Hospital (Site 1059)
Pittsburgh, Pennsylvania
Rhode Island Hospital (Site 1033)
Providence, Rhode Island
Medical University of South Carolina - PPDS (Site 1003)
Charleston, South Carolina
Statcare Pulmonary Consultants - Knoxville (Site 1031)
Knoxville, Tennessee
Vanderbilt University Medical Center (Site 1027)
Nashville, Tennessee
CHI St. Luke's Health Baylor College of Medicine Medical Center (Site 1044)
Houston, Texas
Houston Methodist Hospital (Site 1009)
Houston, Texas
University of Utah - PPDS (Site 1049)
Salt Lake City, Utah
University of Washington Medical Center - Montlake (Site 1067)
Seattle, Washington
Hospital Provincial Dr. Jose M. Cullen ( Site 1902)
Santa Fe, Argentina
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.